8 active shortage notices across 5 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Australia | critical | 3 | 15 Apr 2026 | 31 Dec 2026 | TGA |
| European Union | high | 1 | 7 Oct 2026 | — |
| Belgium | high | 1 | 29 Jun 2026 | 31 Jul 2027 | FAMHP |
| Portugal | medium | 2 | 9 Jun 2026 | — | INFARMED |
| Norway | medium | 1 | 3 Jul 2026 | 30 Jun 2027 | NOMA |
Yes. As of the latest regulator updates, Aztreonam has 8 active shortage notices across 5 countries (Australia, European Union, Belgium, Portugal, Norway). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Aztreonam shortages to causes not stated by the regulator, manufacturing problems, supply-chain disruption. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 28 Aug 2026 to 31 Jul 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Ceftriaxone · Cefotaxime · Ceftazidime-Pentahydrate · Cefepime Hydrochloride · Cefprozil · Cefuroxime
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.